NKF

April 1 - 2025

Supporting materials

POSTER: Patient Baseline Characteristics in the Ongoing Phase 3 VISIONARY Trial: A Randomized, Placebo-Controlled Study of Sibeprenlimab for Immunoglobulin A Nephropathy